



## Clinical trial results: Combined biological treatment and chemotherapy for patients with inoperable cholangiocarcinoma (GOX-P)

### Summary

EudraCT number	2008-002367-14
Trial protocol	DK SE
Global end of trial date	31 March 2016

### Results information

Result version number	v1 (current)
This version publication date	29 December 2021
First version publication date	29 December 2021
Summary attachment (see zip file)	Publication #1 (Phase II marker-driven trial of panitumumab...pdf) Publication #2 (Phase II study of gemcitabine oxaliplatin and capecitabine in patients with KRAS exon 2 mutated biliary tract cancers.pdf)

### Trial information

#### Trial identification

Sponsor protocol code	GOX-P
-----------------------	-------

#### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT00779454
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	Vejle Hospital
Sponsor organisation address	Beriderbakken 4, Vejle, Denmark,
Public contact	Clinical Trial Unit, Vejle Hospital, kfe.onko@rsyd.dk
Scientific contact	Clinical Trial Unit, Vejle Hospital, kfe.onko@rsyd.dk

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	20 November 2019
Is this the analysis of the primary completion data?	Yes
Primary completion date	31 March 2016
Global end of trial reached?	Yes
Global end of trial date	31 March 2016
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

To investigate progression free survival in patients with inoperable cholangiocarcinoma with KRAS mutation treated with combination chemotherapy.

To investigate progression free survival in patients with inoperable cholangiocarcinoma without KRAS mutation treated with combination chemotherapy and biological treatment.

Protection of trial subjects:

Antiemetics and other supportive treatment as necessary.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	24 October 2008
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Sweden: 3
Country: Number of subjects enrolled	Denmark: 69
Worldwide total number of subjects	72
EEA total number of subjects	72

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	24
From 65 to 84 years	48



## Subject disposition

### Recruitment

Recruitment details:

Patients were included between October 2008 and January 2015

### Pre-assignment

Screening details:

Institution based screening of all patients with biliary tract cancer.

### Period 1

Period 1 title	Overall trial (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	Yes
------------------------------	-----

<b>Arm title</b>	Arm A, patients with KRAS mutation
------------------	------------------------------------

Arm description:

Combination chemotherapy according to institutional guidelines

Arm type	Experimental
Investigational medicinal product name	Gemcitabin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate and solvent for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

1000 mg/m<sup>2</sup> every two weeks

Investigational medicinal product name	Oxaliplatin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate and solvent for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

60 mg/m<sup>2</sup> every two weeks

Investigational medicinal product name	Capecitabin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

1000 mg/m<sup>2</sup> twice daily seven days every two weeks

<b>Arm title</b>	Arm B, patients without KRAS mutation
------------------	---------------------------------------

Arm description:

Combination chemotherapy according to institutional guidelines + panitumumab

Arm type	Experimental
----------	--------------

Investigational medicinal product name	Panitumumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use
Dosage and administration details: 6 mg/kg every two weeks	
Investigational medicinal product name	Gemcitabin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate and solvent for solution for infusion
Routes of administration	Intravenous use
Dosage and administration details: 1000 mg/m <sup>2</sup> every two weeks	
Investigational medicinal product name	Oxaliplatin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate and solvent for solution for infusion
Routes of administration	Intravenous use
Dosage and administration details: 60 mg/m <sup>2</sup> every two weeks	
Investigational medicinal product name	Capecitabin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details: 1000 mg/m <sup>2</sup> twice daily seven days every two weeks	

<b>Number of subjects in period 1</b>	Arm A, patients with KRAS mutation	Arm B, patients without KRAS mutation
Started	26	46
Completed	26	46

## Baseline characteristics

### Reporting groups

Reporting group title	Overall trial
-----------------------	---------------

Reporting group description: -

Reporting group values	Overall trial	Total	
Number of subjects	72	72	
Age categorical			
Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	0	0	
Adults (18-64 years)	24	24	
From 65-84 years	48	48	
85 years and over	0	0	
Age continuous			
Units: years			
median	67.5		
full range (min-max)	37 to 86	-	
Gender categorical			
Units: Subjects			
Female	48	48	
Male	24	24	

## End points

### End points reporting groups

Reporting group title	Arm A, patients with KRAS mutation
Reporting group description:	
Combination chemotherapy according to institutional guidelines	
Reporting group title	Arm B, patients without KRAS mutation
Reporting group description:	
Combination chemotherapy according to institutional guidelines + panitumumab	

### Primary: PFS at six months

End point title	PFS at six months
End point description:	
End point type	Primary
End point timeframe:	
6 months	

End point values	Arm A, patients with KRAS mutation	Arm B, patients without KRAS mutation		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	26	46		
Units: Fraction				
arithmetic mean (confidence interval 95%)	52 (31 to 69)	74 (58 to 84)		

### Statistical analyses

Statistical analysis title	Non-parametric
Statistical analysis description:	
Descriptive analyses	
Comparison groups	Arm A, patients with KRAS mutation v Arm B, patients without KRAS mutation
Number of subjects included in analysis	72
Analysis specification	Pre-specified
Analysis type	other <sup>[1]</sup>
P-value	< 0.05
Method	Fisher exact

Notes:

[1] - Each group described individually.

## Adverse events

### Adverse events information<sup>[1]</sup>

Timeframe for reporting adverse events:

Every 4 weeks

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	CTCAE
-----------------	-------

Dictionary version	3
--------------------	---

### Reporting groups

Reporting group title	Toxicity
-----------------------	----------

Reporting group description: -

Notes:

[1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported.

Justification: Only approved and well-known drugs were given.

Serious adverse events	Toxicity		
Total subjects affected by serious adverse events			
subjects affected / exposed	37 / 72 (51.39%)		
number of deaths (all causes)	69		
number of deaths resulting from adverse events	0		
Investigations			
Reduced general condition			
subjects affected / exposed	2 / 72 (2.78%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Cardiac disorders			
Myocardial infarction			
subjects affected / exposed	2 / 72 (2.78%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			
Syncope			
subjects affected / exposed	1 / 72 (1.39%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
Pain			

subjects affected / exposed	7 / 72 (9.72%)		
occurrences causally related to treatment / all	0 / 8		
deaths causally related to treatment / all	0 / 0		
<b>Fatigue</b>			
subjects affected / exposed	8 / 72 (11.11%)		
occurrences causally related to treatment / all	3 / 10		
deaths causally related to treatment / all	0 / 0		
<b>Blood and lymphatic system disorders</b>			
<b>Febrile neutropenia</b>			
subjects affected / exposed	1 / 72 (1.39%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Gastrointestinal disorders</b>			
<b>Abdominal pain</b>			
subjects affected / exposed	2 / 72 (2.78%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 1		
<b>Nausea</b>			
subjects affected / exposed	2 / 72 (2.78%)		
occurrences causally related to treatment / all	2 / 3		
deaths causally related to treatment / all	0 / 0		
<b>Constipation</b>			
subjects affected / exposed	4 / 72 (5.56%)		
occurrences causally related to treatment / all	0 / 6		
deaths causally related to treatment / all	0 / 0		
<b>Vomiting</b>			
subjects affected / exposed	1 / 72 (1.39%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Gastric ulcer</b>			
subjects affected / exposed	1 / 72 (1.39%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Diarrhoea</b>			

subjects affected / exposed	4 / 72 (5.56%)		
occurrences causally related to treatment / all	3 / 5		
deaths causally related to treatment / all	0 / 0		
<b>Ascites</b>			
subjects affected / exposed	2 / 72 (2.78%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
<b>Dyspepsia</b>			
subjects affected / exposed	2 / 72 (2.78%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
<b>Respiratory, thoracic and mediastinal disorders</b>			
<b>Dyspnoea</b>			
subjects affected / exposed	1 / 72 (1.39%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Lung infection</b>			
subjects affected / exposed	1 / 72 (1.39%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Respiratory disorder</b>			
subjects affected / exposed	1 / 72 (1.39%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Hepatobiliary disorders</b>			
<b>Gallbladder obstruction</b>			
subjects affected / exposed	5 / 72 (6.94%)		
occurrences causally related to treatment / all	0 / 6		
deaths causally related to treatment / all	0 / 0		
<b>Cholecystitis</b>			
subjects affected / exposed	5 / 72 (6.94%)		
occurrences causally related to treatment / all	0 / 6		
deaths causally related to treatment / all	0 / 0		

Skin and subcutaneous tissue disorders			
Pruritus			
subjects affected / exposed	1 / 72 (1.39%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Fever			
subjects affected / exposed	17 / 72 (23.61%)		
occurrences causally related to treatment / all	20 / 35		
deaths causally related to treatment / all	0 / 6		
Infection			
subjects affected / exposed	5 / 72 (6.94%)		
occurrences causally related to treatment / all	11 / 12		
deaths causally related to treatment / all	0 / 0		
Sepsis			
subjects affected / exposed	1 / 72 (1.39%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Metabolism and nutrition disorders			
Hypomagnesaemia			
subjects affected / exposed	1 / 72 (1.39%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Dehydration			
subjects affected / exposed	1 / 72 (1.39%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Toxicity		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	0 / 72 (0.00%)		



## **More information**

### **Substantial protocol amendments (globally)**

Were there any global substantial amendments to the protocol? No

---

### **Interruptions (globally)**

Were there any global interruptions to the trial? No

### **Limitations and caveats**

None reported